Skip to main content
Addgene

pBabe puro-eIF4E
(Plasmid #33252)

Full plasmid sequence is not available for this item.

Loading...

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 33252 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pBabe puro
  • Backbone size w/o insert (bp) 5169
  • Vector type
    Mammalian Expression, Retroviral
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    eIF4E
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    1000
  • Mutation
    unmodified
  • Entrez Gene
    EIF4E (a.k.a. AUTS19, CBP, EIF4E1, EIF4EL1, EIF4F, eIF-4E)
  • Promoter SV40
  • Tag / Fusion Protein
    • untagged

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site SnaBI (unknown if destroyed)
  • 3′ cloning site SnaBI (unknown if destroyed)
  • 5′ sequencing primer CTTTATCCAGCCCTCAC
  • (Common Sequencing Primers)

Resource Information

  • A portion of this plasmid was derived from a plasmid made by
    from Dong-Er Zhang, University of California at San Diego, La Jolla, CA from the pHA-eIF4E construct Addgene plasmid 17343
  • Articles Citing this Plasmid

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pBabe puro-eIF4E was a gift from Thomas Roberts (Addgene plasmid # 33252 ; http://n2t.net/addgene:33252 ; RRID:Addgene_33252)
  • For your References section:

    PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Ilic N, Utermark T, Widlund HR, Roberts TM. Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):E699-708. Epub 2011 Aug 29. 10.1073/pnas.1108237108 PubMed 21876152